DiaPharma Group, Inc.

We specialize in biomarkers for toxicology (drug-induced liver and kidney injury), liver disease, oncology, and hemostasis



Featured Products are K18 biomarkers from VLVBio AB

VLVbio AB combines the innovative will and energy of a company founded in 2013 with the history and built-in expertise of a Product Line invented more than a decade ago at the Karolinska Institute in Stockholm, Sweden.

Bringing innovative high-quality biomarker assays to DILI research.





Biomarkers of Drug-Induced Liver Injury



Time/ Drug-induced liver injury

All products are for research use only ML-00-00675 Rev01



Biomarkers of Drug-Induced Kidney Injury



Time/ Drug-induced kidney injury

All products are for research use only ML-00-00675 Rev01

VLVbio

Use of new biomarkers

Featuring Keratin 18

- Increase tissue specificity
- Provide mechanistic information
- Predict liver injury at earlier time points than ALT
- Current uses:

- K18 as a secondary level of investigation if the first biomarkers indicate liver issues
 - Company has already identified a potential liver signal and is trying to gain some mechanistic understanding about the signal. (eg, observed elevated ALT to determine if the injury is primarily necrotic or apoptotic)
- K18 as a first line in cases where liver toxicity is a known issue
 - (ie, immuno-oncology drug investigations)



Keratin 18 in the human body

Almost all cells of epithelial origin:

- Liver
- Lung
- Intestines
- Kidney
- Breast tissue
- Prostate
- Ovary

5



All products are for research use only ML-00-00675 Rev01

PEVIVA







Apoptosis and Necrosis





PEVIVA Product Line

Overview

ELISA Products

- M30 Apoptosense[®] ELISA
- M30 CytoDeath[™] ELISA
- M65[®] ELISA
- M65 EpiDeath[®] ELISA



Antibody Products

 M30 CytoDEATH [™] mAb M6 & M5 Keratin 18 mAb





PEVIVA Product Line

Overview

Product	Apoptosis	Total Cell Death	CellCultures	Spheroids	Xenografts	Blood / Plasma Samples
M30 Apoptosense® ELISA*	~	-	~	~	<i>v</i>	~
M30 CytoDeath™ ELISA	~	-	~	V	-	-
M65® ELISA*	-	V	~	V	v	V
M65 EpiDeath® ELISA	-	4	~	V	4	V



PEVIVA Product Line

Determination of Cell Death Mode

- Products can be useful to quantify:
 - Apoptosis alone (M30)
 - Total cell death (M65)
 - Apoptosis and necrosis (M30 and M65)





Drug-Induced Liver Injury Biomarker

Numerous ongoing research for use of K18 in DILI

- Letters of Support EMA and FDA: Keratin 18 and Osteopontin
- Comparison to traditional biomarkers (ie, ALT) with APAP or exercise
- Drugs (ie, Heparins) showing elevations in ALT/AST, miR-122 without presence of clinically significant liver injury
- Drugs meeting stopping criteria as outlined by FDA for potential hepatotoxicity may not results in serious liver injury with use of new biomarkers and mathematical modeling (ie, Cimaglermin alfa)
- Toxicant-Associated Steatohepatitis (TASH)
- Alcohol related liver damage

→ All of the above research studies using human samples. Previous K18 biomarkers did not detect mouse or rat K18 resulting in limitations in various preclinical models



Introduction of M65® EpiRat ELISA



M65® EpiRat ELISA

- Production of the new rodent-detecting antibody (monoclonal).
- 95 clones selected after mice immunization, 7 clones selected for further testing.
- Only rat, does not detect K18 from mouse!
- M65 EpiRat is born!
- The M65 EpiRat[™] ELISA is based on the <u>M5 and M6 antibodies</u>, which bind to the biomarker Keratin-18 (K18). The concentration of K18 reflects the <u>amount of overall cell death</u>, <u>both apoptosis and</u> <u>necrosis</u>, in K18 positive cells. Levels of K18 are commonly elevated when the liver endures damage, through disease or toxicological effects.





M65 EpiRat[™] ELISA treated with Acetaminophen



Serum samples from untreated rats and rats treated with different doses of APAP were run using the M65 EpiRat™ ELISA. Below you can see results from two runs where rats treated with 1000mg/kg APAP and 1500mg/kg APAP compared to untreated controls. Blood was drawn after 0, 24, and 48 hours.





ELISAs for Drug-Induced Liver Injury (DILI)

ELISAs for Drug-Induced Liver Injury (DILI)

Biomarker	Sample Type	Description	Available Assays	Product #
Keratin 18 (K18)	Serum or plasma	Highly specific biomarker for hepatocyte cell death (necrosis and apoptosis)	Peviva M65® ELISA Peviva M65® Epideath® ELISA	P10020 P10040
Caspase-cleaved Keratin 18 (ccK18)	Serum or plasma	Highly specific biomarker for hepatocyte apoptosis	Peviva M30® Apoptosense	P10011
Osteopontin (OPN)	Serum or plasma	Biomarker for hepatic inflammation and necrosis	Osteopontin Osteopontin N-Half	DPG27158 DPG27258
Alpha Glutathione S-Transferase (α-GST)	Serum or plasma	Short half-life; sensitive to rapid changes in liver damage	TECO Alpha® GST	TE1056
Liver Fatty Acid Binding Protein (L-FABP, FABP1)	Serum or plasma	Sensitive marker for hepatic injury (leakage)	Diapharma L-FABP	DPGLFABP



ELISAs for Drug-Induced Kidney Injury (DIKI)

ELISAs for Drug-Induced Kidney Injury (DIKI)

Biomarker	Sample Type	Description	Available Assays	Product #
Alpha Glutathione S-Transferase (α-GST)	Urine	Biomarker for proximal tubule damage	TECO Alpha® GST	TE1056
Osteopontin (OPN)	Urine	Biomarker for damage to loop of Henle and distal tubule	Osteopontin Osteopontin N-Half	DPG27158 DPG27258
Liver Fatty Acid Binding Protein (L-FABP, FABP1)	Urine	Marker of acute kidney injury; useful for early detection of renal damage accompanying tubular dysfunction	Urinary L-FABP (FABP1)	006
Cystatin C (Cys C)	Serum, plasma, or urine	Assay for estimation of the glomerular filtration rate (GFR); more sensitive than serum creatinine tests	IMD Rapid Cystatin C	31241
Neutrophil Gelatinese- Associated Lipocalin (NGAL)	Urine	Biomarker for distal tubular damage	Diapharma NGAL (96) Diapharma NGAL (2 x 96) IMD Lipocalin-2	DPG-NGAL DPG-2NGAL 31050
Alpha Klotho (α-Klotho)	Plasma	Biomarker of impaired renal function, cytoprotective	FluoBolt™ α-KLOTHO (MEF-FIA)	FIA-1704







